A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours

Veterinary and Comparative Oncology

Volumn 8, Issue 2, 2010, Pages 138-152

  Rassnick, K M ^a   Bailey, D B ^a   Russell, D S ^a   Flory, A B ^a   Kiselow, M A ^a   Intile, J L ^a   Malone, E K ^a   Balkman, C E ^a   Barnard, S M ^a  

^a Cornell University ^*  (United States)

Author keywords

Chemotherapy; Oncology; Small animal

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; LOMUSTINE; PREDNISONE; VINBLASTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; MALE; MASTOCYTOSIS; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME; CHEMICALLY INDUCED; DOG DISEASES; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; FEMALE; LOMUSTINE; MALE; MASTOCYTOSIS; NEOPLASM STAGING; NEUTROPENIA; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 77953928293     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00217.x     Document Type: Article

References (39)

1. Simpson AM, Ludwig LL, Newman SJ, Bergman PJ, Hottinger HA, Patnaik AK. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2004, 224:236-240.
2. Al-Sarraf R, Mauldin GN, Patnaik AK, Meleo KA. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. Journal of Veterinary Internal Medicine 1996, 10:376-378.
3. Weisse C, Shofer FS, Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumors following complete surgical excision. Journal of the American Animal Hospital Association 2002, 38:71-73.
4. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice 1973, 14:27-41.
5. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology 1984, 21:469-474.
6. Turrel JM, Kitchell BE, Miller LM, Theon A. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. Journal of the American Veterinary Medical Association 1988, 193:936-940.
7. Murphy S, Sparkes AH, Smith KC, Blunden AS, Brearley MJ. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Veterinary Record 2004, 154:743-746.
8. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer Engler SJ, Cotter SM. Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 1999, 13:601-605.
9. McCaw DL, Miller MA, Ogilvie GK, Withrow SJ, Brewer WG, Klein MK, Bell FW, Anderson SK. Response of canine mast cell tumors to treatment with oral prednisone. Journal of Veterinary Internal Medicine 1994, 8:406-408.
10. Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 2008, 232:53-62.
11. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999, 13:491-497.
12. Henry CJ, Downing S, Rosenthal RC, Klein MK, Meleo K, Villamil JA, Fineman LS, McCaw DL, Higginbotham ML, McMichael J. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. American Journal of Veterinary Research 2007, 68:1246-1251.
13. Rassnick KM, Bailey DB, Flory AB, Balkman CE, Kiselow MA, Intile JL, Autio K. Efficacy of vinblastine for treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1390-1396.
14. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
15. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
16. Taylor F, Gear R, Hoather T, Dobson J. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. Journal of Small Animal Practice 2009, 50:284-289.
17. Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretin JD, Morrison-Collister K, Cotter SM, Moore AS. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. Journal of Veterinary Internal Medicine 2004, 18:75-80.
18. Intile JL, Rassnick KM, Bailey DB, al Sarraf R, Chretin JD, Balkman CE, Flory AB, Kiselow MA, Wakshlag JJ. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs. Veterinary and Comparative Oncology 2009, 7:69-77.
19. Hosoya K, Lord LK, Lara-Garcia A, Kisseberth WC, London CA, Couto CG. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine). Veterinary and Comparative Oncology 2009, 7:244-255.
20. Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Veterinary and Comparative Oncology 2008, 6:111-119.
21. Camps-Palau MA, Leibman NF, Elmslie R, Lana SE, Plaza S, McKnight JA, Risbon R, Bergman PJ. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Veterinary and Comparative Oncology 2007, 5:156-167.
22. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006, 68:581-587.
23. Hayes A, Adams V, Smith K, Maglennon G, Murphy S. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Veterinary and Comparative Oncology 2007, 5:168-176.
24. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. American Journal of Medicine 1980, 69:585-594.
25. Frei E, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clinical Cancer Research 1998, 4:2027-2037.
26. Bailey DB, Rassnick KM, Kristal O, Chretin JD, Balkman CE. Phase I dose escalation of single-agent vinblastine in dogs. Journal of Veterinary Internal Medicine 2008, 22:1397-1402.
27. Romansik EM, Reilly CM, Kass PH, Moore PF, London CA. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Veterinary Pathology 2007, 44:335-341.
28. Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004, 2:195-213.
29. McCaw DL, Miller MA, Bergman PJ, Withrow SJ, Moore AS, Knapp DW, Fowler D, Johnson JC. Vincristine therapy for mast cell tumors in dogs. Journal of Veterinary Internal Medicine 1997, 11:375-378.
30. Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. Journal of the American Animal Hospital Association 2004, 40:124-130.
31. Chretin JD, Rassnick KM, Shaw NA, Hahn KA, Ogilvie GK, Kristal O, Northrup NC, Moore AS. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. Journal of Veterinary Internal Medicine 2007, 21:141-148.
32. Center SA. Interpretation of liver enzymes. Veterinary Clinics of North America Small Animal Practice 2007, 37:297-333.
33. Cooper M, Tsai X, Bennet P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Veterinary and Comparative Oncology 2009, 7:196-206.
34. Bostock DE, Moriarty J, Crocker J. Correlation between histologic diagnosis mean nucleolar organizer region count and prognosis in canine mammary tumors. Veterinary Pathology 1992, 29:381-385.
35. Simoes JP, Schoning P, Butine M. Prognosis of canine mast cell tumors: a comparison of three methods. Veterinary Pathology 1994, 31:637-647.
36. Chaffin K, Thrall DE. Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis. Veterinary Radiology and Ultrasound 2002, 43:392-395.
37. Murphy S, Sparkes AH, Blunden AS, Brearley MJ, Smith KC. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Veterinary Record 2006, 158:287-291.
38. Takahashi T, Kadosawa T, Nagase M, Matsunaga S, Mochizuki M, Nishimura R, Sasaki N. Visceral mast cell tumors in dogs: 10 cases (1982-1997). Journal of the American Veterinary Medical Association 2000, 216:222-226.
39. Baldi A, Colloca E, Spugnini EP. Lomustine for the treatment of gastrointestinal mast cell tumour in a dog. Journal of Small Animal Practice 2006, 47:465-467.